Qualitative Interviews on the Experience of Orally vs. Intramuscularly Administered Endocrine Therapy for Advanced Breast Cancer: Patient and Healthcare Provider Perspectives.
IF 3.4
Q2 ONCOLOGY
引用次数: 0
Abstract
Introduction: The selective estrogen receptor degraders (SERD) have proven to be an effective treatment option for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). The orally administered next-generation SERDs may be more tolerable and a preferred alternative to the intramuscularly (IM) administered fulvestrant. This study sought to identify patient and healthcare provider (HCP) perspectives on preferences, benefits, burdens, and ease of adherence of oral and IM endocrine therapy (ET).
Methods: Non-interventional, qualitative interviews were conducted in the USA, among adult patients with ER+ HER2- ABC and oncology HCPs. Eligible patients and HCPs had experience with both oral ET and fulvestrant within the past 3 years. One-on-one semi-structured interviews lasted up to 60 min.
Results: We interviewed 25 patients and 20 HCPs. The mean time from BC diagnosis was 12.6 years (standard deviation 8.4); 18 patients (72%) were currently receiving IM and 7 (28%) oral ET. Sixteen patients (64%) preferred oral ET, mainly owing to convenience (13/16, 81%), which was considered the main benefit (22/25, 88%); side effects were a common burden (18/25, 72%). Seven patients preferred IM ET, mainly owing to the monthly injection frequency (6/7, 85%). The primary benefit of IM ET was not having to remember daily dosing (12/22, 55%), and main burdens were injection pain (21/25, 84%) and travel to receive injection (14/22, 64%). Most patients (23/25, 92%) experienced ease of adherence to oral ET. HCPs perspectives were largely aligned to the patients' experiences.
Conclusion: Patients with ER+ HER2- ABC in this study preferred oral to IM ET owing to convenience, and disliked the pain associated with IM ET and travel to receive injections. Compared to IM fulvestrant, oral SERDs may offer an alternative with less burden on the lives of people living with cancer.
对晚期乳腺癌口服与肌内给药内分泌治疗经验的定性访谈：患者和医疗保健提供者的观点。
选择性雌激素受体降解剂（SERD）已被证明是雌激素受体阳性（ER+），人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）患者的有效治疗选择。口服给药的下一代serd可能更具耐受性，是肌注（IM）给药氟维司汀的首选替代方案。本研究旨在确定患者和医疗保健提供者（HCP）对口服和内分泌治疗（ET）的偏好、益处、负担和依从性的看法。方法：在美国对ER+ HER2- ABC和肿瘤学HCPs的成年患者进行非介入性定性访谈。符合条件的患者和HCPs在过去3年内有口服ET和氟维司汀的经历。一对一的半结构化访谈持续了长达60分钟。结果：我们采访了25名患者和20名HCPs。从BC诊断的平均时间为12.6年（标准差8.4）；18名患者（72%）目前正在接受IM治疗，7名患者（28%）正在接受口服ET治疗。16名患者（64%）首选口服ET治疗，主要是因为方便（13/16,81%），这被认为是主要的获益（22/25,88%）；副作用是常见的负担（18/25,72%）。7例患者首选IM ET，主要是由于每月注射频率（6/7,85%）。IM ET的主要好处是不需要记住每天的剂量（12/ 22,55%），主要的负担是注射疼痛（21/ 252,84%）和接受注射的旅行（14/ 22,64%）。大多数患者（23/25,92%）认为口服ET的依从性较好。HCPs的观点在很大程度上与患者的经历一致。结论：本研究中ER+ HER2- ABC患者更倾向于口服ET而非IM ET，因为方便，不喜欢IM ET带来的疼痛和接受注射的旅行。与IM氟维司汀相比，口服serd可能为癌症患者的生活提供一种负担较小的选择。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
来源期刊
Oncology and Therapy
ONCOLOGY-
CiteScore
3.40
自引率
0.00%
发文量
31
审稿时长
6 weeks
期刊介绍：
Now indexed in PubMed
Aims and Scope
Oncology and Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality pre-clinical, clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Oncology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
Rapid Publication
The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid and efficient communication of the latest research and reviews, allowing the advancement of clinical therapies.
Personal Service
The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts.
Digital features and plain language summaries
Oncology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’.
Preprints
We encourage posting of preprints of primary research manuscripts on preprint servers, authors'' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals.
Please see here for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550
Peer Review Process
Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.
At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision.
Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor.
Copyright
Oncology and Therapy''s content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0
Publication Fees
Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of £3650/€4500/$5100. The journal will consider fee discounts for developing countries and this is decided on a case by case basis.
Open Access
All articles published by Oncology and Therapy are published open access
Contact
For more information about the journal, including pre-submission enquiries, please contact managing editor Lydia Alborn at lydia.alborn@springer.com.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
